Related Experiment Video

Updated: Sep 4, 2025

Evaluation of Cardiac Contractility Modulation Therapy in 2D Human Stem Cell-Derived Cardiomyocytes
08:47

Evaluation of Cardiac Contractility Modulation Therapy in 2D Human Stem Cell-Derived Cardiomyocytes

Published on: December 16, 2022

2.5K

Cardiac contractility modulation therapy improves health status in patients with heart failure with preserved

Cecilia Linde1, Marcin Grabowski2, Piotr Ponikowski3

  • 1Heart, Vascular and Neurology Theme, Karolinska University Hospital and the Karolinska Institutet, Stockholm, Sweden.

European Journal of Heart Failure
|July 20, 2022
PubMed

Insights

Cardiac Contractility Modulation (CCM) shows promise for heart failure with preserved ejection fraction (HFpEF) patients. This pilot study found significant health status improvements with CCM therapy, indicating a potential new treatment option for HFpEF.

Area of Science:

  • Cardiology
  • Medical Devices
  • Heart Failure Research

Background:

  • Heart failure with preserved ejection fraction (HFpEF) affects a significant patient population.
  • Current treatment options for HFpEF are limited, highlighting the need for novel therapeutic approaches.
  • Cardiac Contractility Modulation (CCM) is an emerging technology for heart failure management.

Purpose of the Study:

  • To evaluate the safety and efficacy of CCM therapy in patients diagnosed with HFpEF.
  • To assess the impact of CCM on the health status of HFpEF patients.
  • To determine the feasibility of CCM as a treatment for HFpEF.

Main Methods:

  • A prospective, multicentre, single-arm pilot study involving 47 patients with HFpEF (NYHA class II-III).
  • CCM device implantation followed by a 24-week follow-up period.
  • Echocardiographic parameters assessed for eligibility; Kansas City Cardiomyopathy Questionnaire (KCCQ) used for health status evaluation.

Main Results:

  • Significant improvement in KCCQ overall summary score by 18.0 points (p < 0.001).
  • High event-free rate of 93.6% for the primary safety endpoint (device/procedure complications).
  • The study population comprised older adults, predominantly female, with common comorbidities like hypertension and atrial fibrillation.

Conclusions:

  • CCM therapy demonstrates potential benefits in the HFpEF patient population.
  • Significant improvements in health status were observed without compromising safety.
  • CCM may represent a promising therapeutic strategy for managing HFpEF.
Abstract

Keywords:
Cardiac contractility modulationDevice therapyHealth statusHeart failureHeart failure with preserved ejection fractionKansas City Cardiomyopathy Questionnaire

More Related Videos

Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing12:45

Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing

Published on: December 11, 2017

10.6K
Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction09:20

Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction

Published on: February 13, 2021

6.6K

Related Concept Videos

Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
30
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
23
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
20
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
25
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
43
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
501